Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Bhag Karamchandani who wrote (5053)	8/1/1998 11:43:00 AM
From: Izzy	Read Replies (1) \| Respond to of 6136

La sante bon et le bonheur toujours. Boujour.

To: Bhag Karamchandani who wrote (5053)	8/1/1998 12:35:00 PM
From: scaram(o)uche	Respond to of 6136

Bhag: You're implying that some longs lack objectivity. Here's the opinion on Remune that you missed, as you missed my discussions of the Chrioscience MMPI efforts...... "I didn't have any faith in REMUNE as a prophylactic. I had dismissed the product as irrelevant, and IMNR as noise. I've never owned IMNR, and it is my most successful "short" to date. However, it appears that there is a "HAART chronic disease" window to walk through, and that it would be wise to be a player." Message 5097746 Sorry that someone has been emailing you. Have you asked them to stop? You also imply that some longs have lost their objectivity due to desperation. I'm certain that you've actually read this thread before you post, that you believe me, and that you know that I'm not among your ranks of the desperate. I hold only a few far-out-of-the-money calls that, from a profit on puts, are paid for. You continuously ask for assurance that will only be available after the 3340 phase II trials are completed. In the interim, you contribute questions and anxiety, but little or no research. We know that AGPH scientists are working on next-generation MMPIs, and we therefore also know that 3340 is not conceived of as perfect. These facts have been spelled out, with objectivity, by the AGPH bulls. Good luck. Obligatory content of relevance...... AIDS Res Hum Retroviruses 1998 Jun;14 Suppl 2:S167-S175 A primer on HIV type 1-specific immune function and REMUNE. Moss RB, Giermakowska WK, Savary JR, Theofan G, Daigle AE, Richieri SP, Jensen FC, Carlo DJ The Immune Response Corporation, Carlsbad, California 92008, USA. [Medline record in process] The ability to recognize HIV antigens is lost early in HIV-1 infection. Individuals with nonprogressive HIV disease have been observed to mount strong immune responses against the virus and have become a paradigm to emulate with immune-based therapies. Highly active antiviral drug therapy (HAART) has now become the standard of care for HIV-1-infected individuals. Because HIV-specific anergy occurs early in HIV infection, HAART initiated after primary infection may not reconstitute HIV-specific immune function. We have been investigating the effects of an immune-based therapy, called REMUNE, in HIV-1-seropositive individuals. REMUNE has been observed to stimulate HIV-1-specific immune function measured by delayed-type hypersensitivity, lymphocyte proliferation, Th1 cytokine, and beta-chemokine production. Multiple Phase II studies and a Phase III clinical end-point study are ongoing in thousands of seropositive individuals in order to test the clinical utility of REMUNE. The clinical testing of REMUNE and other promising immune-based therapies may provide additional treatment modalities useful in the chronic management of HIV-1.